Product Description
a potential imaging biomarker for _-amyloid burden in brain (Sourced from: https://clinicaltrials.gov/ct2/show/NCT00544453)
Mechanisms of Action: No Mechanism
Novel Mechanism: No
Modality: N/A
Route of Administration: Injection
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Molecular NeuroImaging
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 1: Alzheimer Disease
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
MNI-308-01 | P1 |
Terminated |
Alzheimer Disease |
2007-10-01 |